These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 9774964

  • 1. New monoclonal antibodies to prevent transplant rejection.
    Med Lett Drugs Ther; 1998 Sep 25; 40(1036):93-4. PubMed ID: 9774964
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Daclizumab and basiliximab: monoclonal mouse-man antibodies with effective immunosuppression without side effects].
    ter Meulen CG, Hilbrands LB, van Riemsdijk-van Overbeeke IC, Hené RJ, Christiaans MH, Hoitsma AJ.
    Ned Tijdschr Geneeskd; 2000 Dec 09; 144(50):2396-400. PubMed ID: 11145094
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab.
    Pascual J, Marcén R, Ortuño J.
    Nephrol Dial Transplant; 2001 Sep 09; 16(9):1756-60. PubMed ID: 11522853
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The role of newer monoclonal antibodies in renal transplantation.
    Vincenti F.
    Transplant Proc; 2001 Sep 09; 33(1-2):1000-1. PubMed ID: 11267163
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Daclizumab to prevent acute rejection in renal transplantation.
    Abramowicz D.
    N Engl J Med; 1998 Jun 04; 338(23):1700-1. PubMed ID: 9616069
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The interleukin-2 inhibitors and their role in low-toxicity regimens.
    Nashan B.
    Transplant Proc; 1999 Dec 04; 31(8A):23S-26S. PubMed ID: 10616557
    [No Abstract] [Full Text] [Related]

  • 15. Daclizumab versus anti-thymocyte globulin-fresenius as induction therapy for low-risk kidney transplant recipients.
    Abou-Jaoude MM, Ghantous I, Najm R, Afif C, Almawi WY.
    Transplant Proc; 2003 Nov 04; 35(7):2731-2. PubMed ID: 14612096
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Daclizumab rapidly saturates interleukin-2 receptor-alpha (CD25) on lymph node lymphocytes in children.
    Savo AM, Book BK, Henson S, Hakimi J, Pescovitz MD.
    Transplant Proc; 1999 Nov 04; 31(1-2):1182-3. PubMed ID: 10083528
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Monoclonal antibodies in renal transplantation].
    Bonvoisin C, Weekers L, Grosch S, Krzesinski JM.
    Rev Med Liege; 2009 Nov 04; 64(5-6):287-92. PubMed ID: 19642461
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.